

FDA Staff Manual Guides, Volume I - Organizations and Functions

Department of Health and Human Services

Food and Drug Administration

Center for Drug Evaluation and Research

Office of New Drugs

Office of Cardiology, Hematology, Endocrinology & Nephrology

Effective Date: September 25, 2019

1. Office of Cardiology, Hematology, Endocrinology & Nephrology (DCDGB).


- A. Reviews notices of claimed exemptions for Investigational New Drugs within classes of drugs regulated by this Office and recommends appropriate action with respect to safety and effectiveness of clinical trials.
- B. Evaluates for safety and effectiveness and approves New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for cardiology, hematology, endocrinology, and nephrology products, and evaluates supplements that propose changes in the conditions upon which NDA/BLA approvals are based.
- C. Develops policy and procedures governing the review and evaluation of drug investigations and NDAs/BLAs.
- D. Evaluates and takes appropriate action on recommendations concerning withdrawal of approval of NDAs for cardiology, hematology, endocrinology, and nephrology products.
- E. Performs medical and scientific evaluations of submissions on generic drugs, drugs under monograph, and Over-the-Counter drug products regulated by other offices in the Center, as applicable.
- F. Works collaboratively with the Office of Surveillance and Epidemiology to conduct continuing surveillance and medical evaluation of labeling, clinical experience, and reports submitted by IND sponsors, by NDA and BLA applicants, and from other sources.
- G. Monitors, evaluates, and develops policy for drug labeling.

- H. Initiates necessary actions to maintain industry compliance with drug labeling regulations.
- I. Participates in Agency sponsored consumer and professional educational programs on drug standards.
- J. Develops, in coordination with other Food and Drug Administration (FDA) components, guidance for staff, sponsors and the public that describes the FDA's interpretation of policy on regulatory and scientific issues that involve the office.

2. Authority and Effective Date.

The functional statements for the Office of Cardiology, Hematology, Endocrinology, & Nephrology were approved by the Secretary of Health and Human Services on September 25, 2019.

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of New Drugs
Office of Cardiology, Hematology, Endocrinology & Nephrology**



Staff Manual Guide 1263.30
Organizations and Functions
Effective Date: September 25, 2019

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of for Cardiology, Hematology, Endocrinology & Nephrology organization structure depicting all the organizational structures reporting to the Director.

Office of for Cardiology, Hematology, Endocrinology & Nephrology (DCDGB).

These organizations report to the Office of for Cardiology, Hematology, Endocrinology & Nephrology:

Division of Diabetes, Lipid Disorders, & Obesity (DCDGBA)

Division of General Endocrinology (DCDGBB)

Division of Cardiology & Nephrology (DCDGBD)

Division of Non-Malignant Hematology (DCDGBE)

Division of Pharmacology Toxicology for Cardiology, Hematology, Endocrinology & Nephrology (DCDGBF)